Hubungan Drug Related Problems (DRPs) Obat Antidiabetika terhadap Ketercapaian Kendali Glikemik pada Pasien Rawat Inap Diabetes Melitus Tipe 2 dengan Komplikasi Nyeri Neuropati

https://doi.org/10.22146/jmpf.57829

Anggraini Citra Ryshang Bathari(1), Fita Rahmawati(2*), Ika Puspita Sari(3)

(1) 1) Magister Farmasi Klinik, Fakultas Farmasi, Universitas Gadjah Mada 2) Instalasi Farmasi dan Sterilisasi Rumah Sakit Akademik Universitas Gadjah Mada
(2) Department of Pharmacology, Faculty of Pharmacy, Universitas Gadjah Mada
(3) Fakultas Farmasi, Universitas Gadjah Mada
(*) Corresponding Author

Abstract


Drug Related Problems (DRPs) associated with Type-2 Diabetes Melitus is commonly caused by multi drug prescription since Type-2 Diabetes Mellitus has comorbid dan complication diseases. Neuropathic pain has 50% prevalence of Type-2 diabetes Mellitus Complication. DRPs can cause can cause inadequate therapy that might be the risk factor leads to neuropathic pain. This study was aimed to investigate the association between drug related problems of antidiabetic medication with glicemic control of hospitalized type 2 diabetes melitus with neuropathic pain patients. Cohort-study is used in this study. 50 patients were conducted in this study that underwent Hospital treatment at Rumah Sakit Akademik Universitas Gadjah Mada during the periods of 2018-2019. This study involved 50 patients who were divided into groups that experienced DRPs by 36 patients and non DRPs by 14 patients. All of the 50 has meet the inclusions criterias. Statistical analysis was using Chi-square test 95% confidence interval (p < 0.05). A number of 38 DRPs have found consists of 26,3% need more therapy, 55,2% with wrong drug therapy, 18,4% inadequate dosing. There was an association between DRPs of antidiabetics regiments and glycemic target on Type-2 Diabetes Mellitus patients with neuropathic pain complication (p=0,005). Identification of DRPs is needed to prevent the negative effect of patient therapy outcomes.


Keywords


Drug Related Problems; glycemic target; Type-2 Diabetic mellitus

Full Text:

PDF


References

  1. Juster-Switlyk K, Smith AG. Updates in diabetic peripheral neuropathy. F1000Research. 2016;5(0):1-7.
  2. Cho, N. H., Shaw, J. E., Karuranga, S., et al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Research and Clinical Practice. 2018; 138: 271–281.
  3. Dinas Kesehatan DIY. Provinsi Di Yogyakarta Tahun 2017. Profil Kesehat Provinsi Yogyakarta. 2017;38–9.
  4. Pop-busui R, Boulton AJM, Feldman EL, et al. Diabetic Neuropathy: A Position Statement by the American Diabetes Association. 2017;40 (January):136-154.
  5. Ismail-Beigi F, Craven T, Banerji MA, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: An analysis of the ACCORD randomised trial. Lancet. 2010;376(9739):419-430.
  6. Fowler MJ. Diabetes Foundation: Microvascular and Macrovascular Complications of Diabetes. Clin Diab. 2008;26(3):77-82.
  7. Pharmaceutical care network Europe foundation. Classification for Drug related problems V 8.01. PCNE Classif. Published online 2017:1-10. https://www.pcne.org/upload/files/215_PCNE_classification_V8-01.pdf
  8. Huri HZ, Ling LC. Drug-related problems in type 2 diabetes mellitus patients with dyslipidemia. Published online 2013.
  9. Zaman Huri H, Fun Wee H. Drug related problems in type 2 diabetes patients with hypertension: A cross-sectional retrospective study. BMC Endocr Disord. Published online 2013. doi:10.1186/1472-6823-13-2
  10. Hartuti S, Nasution A, Syafril S. The Effect of Drug-Related Problems on Blood Glucose Level in the Treatment of Patients with Type 2 Diabetes Mellitus. Open Access Maced J Med Sci. 2019 Jun 15; 7(11):1798- 1802.
  11. PERKENI. Indonesia, P. E. (2015). Pengelolaan Dan Pencegahan Diabetes Melitus Tipe 2 Di Indonesia. PB. PERKENI.; 2015.
  12. Moghissi ES, Korytkowski MT, DiNardo M, et al. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Diabetes Care. 2009;32(6):1119-1131.
  13. Silver B, Ramaiya K, Andrew SB, et al. EADSG Guidelines: Insulin Therapy in Diabetes. Diabetes Ther. 2018;9(2):449-492.
  14. Dormandy JA, Charbonnel B, Eckland DJA, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): A randomised controlled trial. Lancet. 2005;366(9493):1279-1289.
  15. Moon MK, Hur KY, Ko S, et al. Combination therapy of oral hypoglycemic agents in patients with type 2 diabetes mellitus. Published online 2017:974-983.
  16. Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes. 1996;45(12):1661-1669.
  17. Draznin B, Gilden J, Golden SH, et al. Pathways to quality inpatient management of hyperglycemia and diabetes: A call to action. Diabetes Care. 2013;36(7):1807-1814.
  18. Strowig SM, Raskin P. Combination therapy using metformin or thiazolidinediones and insulin in the treatment of diabetes mellitus. Published online 2005:633-641.
  19. Yamanouchi T, Press D. Concomitant therapy with pioglitazone and insulin for the treatment of type 2 diabetes. Published online 2010:189-197.
  20. Berhanu P, Perez A, Yu S. Effect of pioglitazone in combination with insulin therapy on glycaemic control, insulin dose requirement and lipid profile in patients with type 2 diabetes previously poorly controlled with combination therapy. Published online 2007:512-520.
  21. Porcellati F, Lucidi P, Cioli P, et al. Pharmacokinetics and pharmacodynamics of insulin glargine given in the evening as compared with in the morning in type 2 diabetes. Diabetes Care. 2015;38(3):503-512.
  22. Wang Z, Hedrington MS, Joy NG, et al. Dose-response effects of insulin glargine in type 2 diabetes. Diabetes Care. 2010;33(7):1555-1560.
  23. Rodbard HW, Visco VE, Andersen H, et al. Treatment intensification with stepwise addition of prandial insulin aspart boluses compared with full basal-bolus therapy (FullSTEP Study): A randomised, treat-to-target clinical trial. Lancet Diabetes Endocrinol. 2014;2(1):30-37.
  24. Handelsman Y, Bloomgarden ZT, Grunberger G, et al. American Association of Clinical Endocrinologists and American College of Endocrinology - Clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015. Endocr Pract. 2015;21(4):1-87.
  25. Cipolle RJ, Strand LM, Morley PC. Pharmaceutical Care Practice:; 2012.
  26. Yigazu DM, Desse TA. Glycemic control and associated factors among type 2 diabetic patients at Shanan Gibe Hospital, Southwest Ethiopia. BMC Res Notes. 2017;10(1):1-6.
  27. Juarez DT, Sentell T, Tokumaru S, et al. Factors Associated With Poor Glycemic Control or Wide Glycemic Variability Among Diabetes Patients in Hawaii, 2006 – 2009. 2012;9:1-10.
  28. Bc C, Aa L, El F, et al. Enhanced glucose control for preventing and treating diabetic neuropathy (Review). 2012;(6).
  29. American Diabetes Association. Diabetes care. Standars of Medical Care in Diabetes:; 2019
  30. Wells BG, DiPiro CV, DiPiro JT, et al. Endocrinologic Disorder: Diabetes Mellitus. Pharmacotherapy Handbook 9th Edition.” McGraw-Hill Education. 2014; (19):161-175.
  31. Inzucchi SE, Maggs DG, Spollett GR, et al. Efficacy and Metabolic Effects of Metformin and Troglitazone in Type II Diabetes Mellitus. New England Journal of Medicine. 1998; 338 (13): 867–873.




DOI: https://doi.org/10.22146/jmpf.57829

Article Metrics

Abstract views : 5005 | views : 8463

Refbacks

  • There are currently no refbacks.


Copyright (c) 2020 JURNAL MANAJEMEN DAN PELAYANAN FARMASI (Journal of Management and Pharmacy Practice)

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

©Jurnal Manajemen dan Pelayanan Farmasi
Faculty of Pharmacy
Universitas Gadjah Mada
Creative Commons License
View My Stats